19.05.2011 • NewsGen-ProbeThermo FisherNovartis

Bidders Emerge For Gen-Probe, Phadia

Bidders emerged for allergy-testing company Phadia and diagnostic test-maker Gen-Probe, according to The Wall Street Journal.

Laboratory equipment company Thermo Fisher Scientific is a leading contender for privately owned Phadia, and is involved in the auction for Gen-Probe, the newspaper reported in its online edition.

Phadia could fetch as much as $3 billion in a sale, while Gen-Probe has a market capitalization of $3.8 billion.

Other bidders for Gen-Probe include Novartis, and Life Technologies Corp, the newspaper said.

Gen-Probe, Phadia, Thermo Fisher declined to comment. Life Technologies and Novartis, which has a partnership with Gen-Probe, could not be immediately reached for comment.

Last month, Gen-Probe hired Morgan Stanley to seek a buyer for the company, sources familiar with the situation said.

 

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.